A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject7 Compared to VIAject25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin (Primary) ; Insulin lispro
Indications Type 1 diabetes mellitus
Focus Pharmacokinetics
Sponsors Biodel

Most Recent Events

15 Mar 2012 Planned patient number 44 added as reported by EudraCT.
01 Mar 2012 Results published in Diabetes, Obesity and Metabolism.
15 Nov 2010 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight